IP Library Granted Patent US 11,186,867
Granted Patent B2
US 11,186,867 · App. 15/448,966 · Granted Nov 30, 2021

Next generation genomic sequencing methods

Inventors: Luke T. Daum (San Antonio, TX); Gerald W. Fischer (Bethesda, MD)
Assignee: Longhorn Vaccines and Diagnostics, LLC
C12Q1/6869C12Q1/689C12Q1/701C12Q2600/156C12Q2600/16Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,186,867
App. No.
15/448,966
Granted
Nov 30, 2021
Kind
B2
Abstract

Disclosed is an enhanced method for rapid and cost-effective analysis of sequences of a microorganism by semi-conductor sequencing, preferably ion-torrent sequencing. This method provides for full length analysis and of multiple areas (e.g. genes) of multiple genomes. These methods identify genetic mutations of a particular gene that are responsible for conferring resistance or sensitivity to an antibiotic or other chemical compound. Multiple different species, strains and/or serotypes of a particular organism are rapidly and efficiently screened and mutations identified along with the complete genome of an organism. By selecting primers pairs of similar size and GC content that produce amplicons with sequences spanning the entire genome, a single PCR reaction analyzed by ion torrent methodology can determine the sequence of a complete genome. Methods are useful to sequences the genomes of viral agents, such as influenza virus, and bacterial agents, such as tuberculosis bacteria.

Claims (31)

1. A mixture comprising multiple pairs of nucleic acid primers wherein,

each primer is from about 15 to about 25 nucleotides in length;

each primer has a GC content of from about 25% to about 45%;

the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of the genome of a Mycobacteria, wherein the multiple pairs contain nucleic acid primers that hybridize with portions of sequences of genes that confer resistance to the Mycobacteria of multiple agents selected from the group consisting of rifampin, isoniazid, fluoroquinolone, pyrazinamide, aminoglycoside, amikacin, kanamycin, capreomycin and streptomycin; and

the different portions are spaced about 500 to about 2,000 nucleotides apart along the entire sequence of the genome.

2. The mixture of claim 1 , wherein each primer of the multiple pairs of nucleic acid primers has a similar annealing temperature to the nucleic acid.

3. The mixture of claim 2 , wherein the similar annealing temperature is within about 5° C.

4. The mixture of claim 2 , wherein the similar annealing temperature is within about 3° C.

5. The mixture of claim 1 , wherein the different portions are spaced about 800 to about 1,500 nucleotides apart.

6. The mixture of claim 1 , which is maintained at room temperature and does not require refrigeration.

7. The mixture of claim 1 , wherein the Mycobacteria is Mycobacterium tuberculosis.

8. The mixture of claim 1 , wherein the nucleic acid primers do not self-hybridize.

9. The mixture of claim 1 , further containing a heat-stable polymerase, a mix of deoxynucleotide tri phosphates comprising dATP, dCTP, dGTP and dTTP, a chelating agent, a salt, a buffer, a stabilizing agent, and/or nuclease-free water.

10. The mixture of claim 1 , further containing a reverse transcriptase, a mix of deoxynucleotide tri phosphates comprising about equivalent amounts of dATP, dCTP, dGTP and dTTP, a chelating agent, an osmolarity agent, an albumin, a magnesium salt, and/or a buffer.

11. The mixture of claim 1 , which, when the mixture and the genome are subjected to a polymerase chain reaction, generates a collection of amplicons, such that the entire sequence of the genome is represented in the resulting collection of amplicons.

12. The mixture of claim 11 , wherein the collection comprises amplicons that are from about 500 to 2,000 nucleotides.

13. The mixture of claim 1 , wherein each of the primers of the multiple primer pairs is from about 16 to about 24 nucleotides in length.

14. The mixture of claim 1 , wherein each of the primers of the multiple primer pairs has a GC content of about 28% to about 35%.

15. The mixture of claim 1 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to at least three of the multiple agents.

16. The mixture of claim 1 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to at least five of the multiple agents.

17. The mixture of claim 1 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to at least seven of the multiple agents.

18. The mixture of claim 1 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to all of the multiple agents.

19. The mixture of claim 11 , where the collection of amplicons includes one or more amplicons of sequences of genes that confer resistance to the Mycobacteria of multiple agents selected from the group consisting of rifampin, isoniazid, fluoroquinolone, pyrazinamide, aminoglycoside, amikacin, kanamycin, capreomycin and streptomycin.

20. A mixture comprising multiple pairs of nucleic acid primers wherein,

the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of the genome of a Mycobacteria, wherein the multiple pairs contain nucleic acid primers that hybridize with portions of sequences of genes that confer resistance to the Mycobacteria of multiple agents selected from the group consisting of rifampin, isoniazid, fluoroquinolone, pyrazinamide, aminoglycoside, amikacin, kanamycin, capreomycin and streptomycin;

wherein, when the mixture and the genome are subjected to a polymerase chain reaction, generates a collection of amplicons that includes one or more amplicons of sequences of genes that confer resistance to the Mycobacteria of multiple agents selected from the group consisting of rifampin, isoniazid, fluoroquinolone, pyrazinamide, aminoglycoside, amikacin, kanamycin, capreomycin and streptomycin.

21. The mixture of claim 20 , wherein each primer is from about 15 to about 25 nucleotides in length; each primer has a GC content of from about 25% to about 45%, each primer has a similar annealing temperature, and/or the different portions are spaced about 500 to about 2,000 nucleotides apart along the entire sequence of the genome.

22. The mixture of claim 20 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to at least three of the multiple agents.

23. The mixture of claim 20 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to at least five of the multiple agents.

24. The mixture of claim 20 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to at least seven of the multiple agents.

25. The mixture of claim 20 , wherein the multiple pairs of nucleic acid primers contain sequences that correspond to different portions of genes that confer resistance to all of the multiple agents.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: DAUM, LUKE T.; FISCHER, GERALD W.
To: LONGHORN VACCINES AND DIAGNOSTICS, LLC
Reel/Frame 041459/0754 →
Continuity (8)
Continuation 14527281 · Oct 29, 2014
Continuation 13890512 · May 9, 2013
Provisional Application 61897015 · Oct 29, 2013
Provisional Application 61737250 · Dec 14, 2012
Provisional Application 61695960 · Aug 31, 2012
Provisional Application 61646060 · May 11, 2012
Provisional Application 61644876 · May 9, 2012
Related Publication 20170183725A1 · Jun 29, 2017